IUH Trial ChartsDiabetes Threshold5678910Baseline10 Weeks9.07.26.26.95.86.1Average HbA1c (%)Baseline HbA1c (%)7.5n=966.5–7.4n=95<6.5n=47 IUH Trial Charts100%80%60%40%20%0%Percent of users with dosage change93%86%60%57%30%28%100%75%11%6%87%36%93%90%EliminatedReducedInsulinsSulfonylureasSGLT-2 InhibitorsDPP-4 InhibitorsGLP-1 Receptor AgonistsThiazolidinedionesMetforminn=78n=62n=29n=4n=30n=43n=193 IUH Trial ChartsBaseline10 Weeksaverage decrease in triglycerides22%20016018012014010080Time in Virta ClinicAverage triglycerides (mg·dL-¹)185145 IUH Trial Charts01098765Weeks in Virta Clinic43210%-5%-10%-15%Body weight loss-7.2% Diabetes Reversal (1 year) Virta 60% Bariatric Surgery40% Usual Care1% A1c Improments (1 year) Virta-1.3% Usual Care+0.1% Medication Reductions (1 year) 94% Detailed Medication Reductions (1 year) -100% -80% -60% -40% -20% 0% All Diabetes Meds -4 8 % Sulfonylurea -10 0% Insulin -4 4% Thiazolidinedione - 73% SGLT-2 - 91% DPP-4 - 36% Statin - 7% Metformin - 9% Blood Pressure - 17% GLP-1 7%

Our results demonstrate that Virta can sustain reversal of type 2 diabetes and other chronic metabolic diseases

Our ongoing study, conducted in partnership with Indiana University Health Arnett, is a non-randomized trial evaluating health outcomes of patients who select to participate in the outpatient continuous care intervention (Virta Treatment) and those who select to receive usual care from their physicians and diabetes educators.

The intervention involves nutrition and behavior change education, support from health coaches and peers, and medication management by physicians.

Trial at a Glance
  • 262 participants with type 2 diabetes receiving the Virta Treatment
  • 87 participants with type 2 diabetes receiving Usual Care
  • 5-year outpatient protocol

Groundbreaking Clinical Outcomes

Virta's landmark clinical trial demonstrated rapid type 2 diabetes reversal in as little as 10 weeks, with sustained and improved results at 1 year—all published in peer-reviewed scientific journals.

  • 60%
    of patients reversed
    their type 2 diabetes 
  • 94%
    of patients reduced
    or eliminated insulin 
  • 1.3%
    Average HbA1c reduction
    at one year 
  • 30 lbs
    avg weight loss at
    one year (12%) 
  • 83%
    clinical trial retention
    at one year 
Hallberg SJ, McKenzie AL, Williams P, et al. Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at One Year: An Open Label, Non-Randomized, Controlled Study. Diabetes Ther. 2018. DOI: 10.1007/s13300-018-0373-9

How does the Virta Treatment compare to Usual Care?

Virta Usual Care
HbA1c ▼ -1.3% ▲ +0.2%
Diabetes Medication Usage Rate (except metformin) ▼ -48% ▲ +9%
Body Weight ▼ -30 lbs ▬ +0 lbs
Triglycerides ▼ -48 mg/dL ▲ +28 mg/dL
HDL-c ▲ +8 mg/dL ▲ -1 mg/dL
Inflammation (hsCRP) ▼ -39% ▲ +15%

Hallberg SJ, McKenzie AL, Williams P, et al. Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at One Year: An Open Label, Non-Randomized, Controlled Study. Diabetes Ther. 2018. DOI: 10.1007/s13300-018-0373-9

Citations

While the Virta Treatment is a novel approach to treating type 2 diabetes and other chronic metabolic diseases, an extensive body of research exists on the foundation of our care model.